A Phase 3 interventional study of Placebo Nasal Aerosol and Prednisone capsules in Perennial Allergic Rhinitis, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 3 sites in United States. Open to participants aged 12 Years to 45 Years. Per ClinicalTrials.gov, last updated 2012-07-04.
Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Rhinitis, Allergic, Perennial with a site in United States — none open to participants now, 1 under way, 1 of them phase 3. Rhinitis, Allergic, Perennial · United States.
Among the 60 studies in Rhinitis, Allergic, Perennial with a site in United States, this one is the 36th largest by enrollment of the 57 interventional ones that give a count, is one of 5 that started in 2010, is one of 33 in phase 3, and was the 43rd registered.
178 studies on the registry are indexed under Rhinitis, Allergic, Perennial; 9 are open to participants now.
Browse Rhinitis, Allergic, Perennial studies →None of the 60 studies in Rhinitis, Allergic, Perennial with a site in United States is open now. The open studies under Rhinitis, Allergic, Perennial, anywhere →
Of the 3 Rhinitis, Allergic, Perennial studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 12 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 5 · Phase 3 33 · Phase 4 14
First in 2000; this study’s year is marked. 5 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 107 is below the median of 135 across 157 interventional studies indexed under Rhinitis, Allergic, Perennial.
Median enrollment 301 across the 57 interventional studies, 824 across the 3 observational. Of the 58 that completed or were terminated, 37 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 60 have an industry lead sponsor. The 10 most frequent:
This study is registered under Teva Branded Pharmaceutical Products R&D, Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Teva Branded Pharmaceutical Products R&D, Inc. is the lead sponsor of 206 studies on the registry; none are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 47 (96%) have results posted.
Teva Pharmaceutical Industries, Ltd. has 4 studies filed under Rhinitis, Allergic, Perennial — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 60 studies in Rhinitis, Allergic, Perennial with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the effects of BDP HFA Nasal Aerosol on HPA-axis function.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants self-administered 4 actuations (two per nostril) of placebo HFA once daily each morning for 6 weeks (42 days) as double-blind therapy for BDP. During week 6 (days 36-42), participants also took a placebo capsule as double-blind therapy for prednisone.
Drug: Placebo Nasal Aerosol · Drug: Placebo Prednisone Capsules
Participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily each morning for 6 weeks (42 days). During week 6 (days 36-42), participants also took a placebo capsule as double-blind therapy for prednisone.
Drug: Placebo Prednisone Capsules · Drug: Beclomethasone dipropionate
Participants self-administered 4 actuations (two per nostril) of placebo HFA once daily each morning for 6 weeks (42 days) as double-blind therapy for BDP. During week 6 (days 36-42), participants also took a 10/mg a day prednisone capsule.
Drug: Placebo Nasal Aerosol · Drug: Prednisone capsules
Placebo nasal aerosol administered daily for 42 days of treatment
Prednisone 10 mg capsule taken each day on the last 7 days of treatment
Placebo prednisone capsule taken each day on the last 7 days of treatment
Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for 42 days.
Also known as: QNASL(TM)
The 24-hour Serum Cortisol Weighted Mean After 42 Days of Treatment
Geometric mean serum cortisol weighted mean values were calculated at baseline and after 6 weeks (42 days) of treatment. The geometric mean ratio of week 6 / baseline is reported. The primary outcome compares the BDP HFA and Placebo treatment arms. The comparison of active control (Placebo/Prednisone) and Placebo treatment arms is an "other pre-specified" outcome.
Time frame: Day 0 (Baseline), Day 42
A total of 139 patients were screened and 128 patients were enrolled in the study and participated in the Run-in Period. Of the 128 enrolled patients, 107 were randomized to study treatment.
| Milestone | BDP HFA 320 µg/Day | Placebo | Placebo/Prednisone |
|---|---|---|---|
| Started | 50 | 46 | 11 |
| Safety population | 50 | 46 | 11 |
| Per protocol population | 48 | 41 | 9 |
| Completed | 49 | 41 | 9 |
| Not completed | 1 | 5 | 2 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 | 2 |
| Withdrew: Other | 0 | 2 | 0 |
Geometric mean serum cortisol weighted mean values were calculated at baseline and after 6 weeks (42 days) of treatment. The geometric mean ratio of week 6 / baseline is reported. The primary outcome compares the BDP HFA and Placebo treatment arms. The comparison of active control (Placebo/Prednisone) and Placebo treatment arms is an "other pre-specified" outcome.
| ratio | BDP HFA 320 µg/Day | Placebo | Placebo/Prednisone |
|---|---|---|---|
| The 24-hour Serum Cortisol Weighted Mean After 42 Days of Treatment | 0.90 ± 1.04 | 0.95 ± 1.03 | 0.31 ± 1.14 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BDP HFA 320 µg/Day | — | 0/50 (0%) | 3/50 (6%) |
| Placebo | — | 0/46 (0%) | 3/46 (6.5%) |
| Placebo/Prednisone | — | 0/11 (0%) | 5/11 (45.5%) |
| Event | BDP HFA 320 µg/Day | Placebo | Placebo/Prednisone |
|---|---|---|---|
| GastroenteritisInfections and infestations | 0/50 | 0/46 | 1/11 |
| Blood oestrogen increasedInvestigations | 0/50 | 0/46 | 1/11 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 0/50 | 0/46 | 1/11 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 2/50 | 1/46 | 1/11 |
| Nasal discomfortRespiratory, thoracic and mediastinal disorders | 1/50 | 2/46 | 1/11 |
| Age Continuous(years) | BDP HFA 320 µg/Day | Placebo | Placebo/Prednisone | Total |
|---|---|---|---|---|
| Mean | 28.3 ± 10.0 | 26.6 ± 10.6 | 26.2 ± 11.9 | 27.4 ± 10.4 |
| Sex: Female, Male(Participants) | BDP HFA 320 µg/Day | Placebo | Placebo/Prednisone | Total |
|---|---|---|---|---|
| Female | 25 | 22 | 7 | 54 |
| Male | 23 | 19 | 2 | 44 |
| Race/Ethnicity, Customized(participants) | BDP HFA 320 µg/Day | Placebo | Placebo/Prednisone | Total |
|---|---|---|---|---|
| Hispanic or Latino | 18 | 17 | 2 | 37 |
| Not Hispanic or Latino | 30 | 24 | 7 | 61 |
| Race/Ethnicity, Customized(participants) | BDP HFA 320 µg/Day | Placebo | Placebo/Prednisone | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 1 | 0 | 0 | 1 |
| Black or African American | 7 | 2 | 1 | 10 |
| White | 42 | 38 | 7 | 87 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
| Body Mass Index(kg/m^2) | BDP HFA 320 µg/Day | Placebo | Placebo/Prednisone | Total |
|---|---|---|---|---|
| Mean | 27.9 ± 7.9 | 27.0 ± 6.2 | 28.4 ± 7.9 | 27.6 ± 7.2 |
The record gives a start of Jun 2010, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2012, 1 year 10 months after primary completion. A results delay was requested in Aug 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Beclomethasone
Rhinitis, Allergic, Perennial →
Teva Branded Pharmaceutical Products R&D, Inc. →